A composite endpoint for acceptability evaluation of oral drug formulations in the pediatric population

Manfred Wargenau PhD¹; Sibylle Reidemeister PhD²; Ingrid Klingmann, MD, PhD³; Viviane Klingmann, MD, PhD⁴

- ¹ M.A.R.C.O. GmbH & Co. KG, Institute for Clinical Research and Statistics, Schirmerstrasse 71, 40211 Düsseldorf, Germany, Manfred.wargenau@marco-institut.de
- ² Novartis Pharma AG, Global Drug Development /Technical Research & Development, Novartis Campus, 4056 Basel, Switzerland, sibylle.reidemeister@novartis.com
- ³ Pharmaplex bv, Avenue Saint-Hubert 51, 1970 Wezembeek-Oppem, Belgium, iklingmann@pharmaplex.be
- ⁴ Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225 Düsseldorf, Germany, Viviane.klingmann@med.uni-duesseldorf.de, telephone: +49 211 81 07906

Corresponding author: Viviane Klingmann, MD, PhD

Key words: Acceptability, swallowability, palatability, patient centricity, oral pediatric formulations

Abstract:

Introduction: A medicine's acceptability is likely to have significant impact on pediatric compliance. EMA and FDA guidance on this topic ask for investigation of acceptability. Although palatability and deglutition are denoted as elements of acceptability, the impact of both on acceptability remains unclear as an unambiguous definition of acceptability is lacking. Actually, globally applied standards for acceptability definition, testing methodology and assessment criteria do not exist. A definition of acceptability establishing a composite endpoint that combines deglutition and palatability in different age groups is presented here.

Methods: This composite acceptability endpoint is based on validated assessment methods for deglutition and palatability in children of different age groups with different galenic placebo formulations, in line with criteria EMA proposed for assessing acceptability in children from newborn to 18 years. Data from two studies investigating mini-tablets, oblong tablets, orodispersible films and syrup were used to investigate the validity, expediency and applicability of the suggested composite acceptability assessment tool.

Results: The new composite endpoint is highly suitable and efficient to distinguish preferences of oral formulations: Mini-tablets and oblong tablets were significantly better accepted than syrup and orodispersible film.

Conclusion: Since the suggested acceptability criterion takes both deglutition and palatability into account as composite endpoint, it is highly sensitive to detect acceptability differences between oral formulations. It is a well-defined, valid approach, which particularly meets regulatory requirements in an appropriate and comprehensive manner and may in future serve as an easy, standardized method to assess and compare acceptability of pediatric formulations with active standardized method to assess and compare acceptability of pediatric formulations with active standardized method to assess and compare acceptability of pediatric formulations with active

Introduction:

The oral route of administration is the most commonly used for pediatric medicines, which are developed according to ethical obligations and regulatory guidelines. The FDA Draft guidance [1] generally asks for "the ethical acceptability", and the EMA guideline [2] states that "... at least considerations for the choice of route(s) of administration, dosage form(s), dosing needs/flexibility and excipients in the preparation and administration device(s) should be discussed, taking into consideration acceptability". In particular, the following aspects are to be considered when selecting an age-appropriate formulation: "The patient acceptability including palatability (e.g., local pain, taste)". Furthermore, this guideline mentions in section 10 another characteristic of acceptability, namely swallowability.

Given the increasing focus to develop patient centric formulations as of today, existing acceptability assessment methodology and approaches are fragmented [3,4], and a harmonized approach is lacking [4]. Actually, comprehensively investigated and globally established standards for acceptability definition, test methods and assessment criteria do not exist: in most published studies the results were based on surveys or observations by parents, cares, healthcare providers or patients, or on underpowered studies with different assessment conditions. In 2013, Klingmann et al. published the results of a standardized, in-person controlled study with mini-tablets and syrup with a statistically defined sample size and defined scores for acceptability and swallowability observed and documented by a trained investigator [6]. In further statistically powered studies this validated method was applied to investigate acceptability of multiple mini-tablets, orodispersible films and oblong tablets [5-10]. However, although palatability and swallowability assessing the act of deglutition are denoted as elements of acceptability, the relationship between these key terms remains unclear.

This project is intended to establish and validate an acceptability test system as a composite endpoint based on deglutition and palatability, for which established, broadly accepted definitions are used (Klingmann et al. [5-10]) in boys and girls from newborn to 18 years across different races comparing four oral pediatric drug formulations: syrup, mini-tablets, capsules and tablets. It is intended to broadly discuss the results with academic and industry experts, clinicians, regulators and patients to provide an internationally accepted method for acceptability assessment. In addition, the suggested acceptability assessment procedure may in future serve as a test system to enable patient centric drug development [11].

Materials and Methods

According to the validated method of Klingmann [12] in children between 2 days and 6 years acceptability can be assessed by observing the act of deglutition and a rapid mouth inspection by a trained investigator. The outcome of the deglutition was described according to the following scoring scheme:

Score	Observation
1	Completely swallowed
2	Partially swallowed (chewed and/or parts of the solids or syrup were found during oral inspection)

3	Spat out
4	Swallowed the wrong way (cough may have been caused)
5	Refused to take

Table 1: Scoring criteria for deglutition

A drug formulation was considered as "acceptable" when it was either "completely swallowed" or "partially swallowed".

Palatability can be described as an expression in mimic, gestures and – in older children - expressed opinion - of an overall appreciation of an oral medicine towards its appearance, smell, taste, after taste and mouth feel (e.g. texture, cooling, heating, trigeminal response) [13].

In two studies in children from newborn to 6 years, Klingmann et al. [9] and Münch et al. [10] validated a method that was based on assessing the palatability by video documentation and independent evaluation by two blinded raters according to the following scoring scheme:

Score	Assessment	Interpretation				
		Positive hedonic pattern:				
1	Pleasant	Tongue protrusion, smack of mouth and lips, finger				
	sucking, corner elevation					
2	Neutral	Neutral mouth & body movements, and face				
	Neutrai	expression				
		Negative aversive pattern:				
3	Unpleasant	Gape, nose wrinkle, eye squinch, frown, grimace,				
		head shake, arm flail				

Table 2: Palatability scoring criteria based on video documentation per rater

The palatability assessments of the two raters are combined according to the following rule:

Scoring of Rater 1	Scoring of Rater 2			
	Pleasant Neutral Unpleasant			
Pleasant	Pleasant	Pleasant	Contradictory	
Neutral	Pleasant	Neutral	Unpleasant	
Unpleasant	Contradictory	Unpleasant	Unpleasant	

Table 3: Combined rater palatability assessment

Assuming that a combination of deglutition and palatability would describe acceptability more precisely, the composite endpoint was developed defining acceptability as 'high', 'good', 'low', or 'no' based on deglutition and combined rater palatability as shown in the following table:

Palatability	Deglutition Score				
	1	2	≥ 3		
Pleasant	High	Good	No		
Neutral	Good	Low	No		
Unpleasant	Low	No	No		
Contradictory	Good	Low	No		

Table 4: Assessment of acceptability as composite endpoint

The validity of this combined criterion for acceptability has been investigated by applying factor analysis. The following variables have been submitted to factor analysis:

- deglutition score (1, 2, 3, 4, 5), refer to table 1
- palatability score (1, 2, 3) for rater 1, refer to table 2
- palatability score (1, 2, 3) for rater 2, refer to table 2.

Results:

Evaluation and validation of acceptability as composite endpoint was performed using the data from two previous studies:

- Study_1: "Acceptability of small-sized oblong tablets in comparison to syrup and mini-tablets in infants and toddlers: A randomized controlled trial", Münch et al. [10]. In total, 280 children stratified into 5 age groups were included (1 to <2 years, 2 to <3 years, 3 to <4 years, 4 to <5 years, 5 to <6 years).
- Study_2: "Acceptability of an orodispersible film compared to syrup in neonates and infants: A randomized controlled trial", Klingmann et al. [9]. In total, 150 children stratified into 3 age groups were included (2 to 28 days, 29 days to 5 months, > 5 to 12 months).

Factor analysis

Factor analysis was separately applied for each formulation, i. e. for syrup, oblong tablets and minitablets from Study_1, and for syrup and orodispersible film from Study_2.

Deglutition, palatability (reader1) and palatability (reader2) were included in the factor analyses. Here, results are exemplarily given for the syrup formulation (Study_1) since it has been widely used and therefore represents an appropriate reference formulation:

The correlation between the three assessments ranged between 0.684 and 0.777 and resulted in a high value of 0.891 for Cronbach's standardized alpha. Factor analysis clearly identified one main component with an eigenvalue of 2.32 (presenting a portion of 77%), other eigenvalues were clearly below 1 with 0.46 and 0.22. Thus, it can be concluded that one dominant main factor exists comprising the information from the three single assessments, and this condensed information can be interpreted as 'acceptability'.

Factor loads for deglutition, palatability (reader1) and palatability (reader2) were found comparable with values of 0.82, 0.91, and 0.90, thus contributing to a similar extent to the main component. This can be presented as linear combination of the single variables by using the above-mentioned factor loads.

The results for acceptability defined as composite endpoint according to table 4 were calculated for the syrup formulation. Each outcome category of acceptability was then related to the outcome of the factor analysis as expressed by the linear combination for the main component (Table 5).

Acceptability		Mean (SD) of
(composite	n (%)	main component
endpoint)		(linear combination)
High	39 (27.7%)	3.21 (0.438)
Good	27 (19.2%)	4.44 (0.017)
Low	12 (8.5%)	5.79 (0.483)
No	63 (44.7%)	7.20 (0.636)

Table 5: Relationship between acceptability rates and main component derived from factor analysis (N = 141) for syrup formulation from Study_1

A high association between acceptability categories and the results from factor analysis can be recognized. Comparison of the acceptability categories with regard to the main component by analysis of variance yielded a p-value < 0.0001.

Thus, the suggested acceptability as composite endpoint can be regarded as a valid approach representing the result of the factor analysis.

Factor analyses were analogously performed for the other 4 formulations (oblong tablets and minitablets from Study_1, and for syrup and orodispersible film from Study_2). In all cases highly consistent results to those presented above for syrup (Study_1) were obtained, thus providing high validity and reliability of the suggested approach for assessing acceptability as composite endpoint.

Application of the acceptability approach as composite endpoint

The two studies considered in this work used deglutition as single criterion for acceptability, the respective results are presented below:

	Study_1			Study_2	
Deglutition	Syrup	Mini-tablet	Oblong tablet	Syrup	ODF
	n (%)	n (%)	n (%)	n (%)	n (%)
Completely swallowed	76 (53.5%)	113 (80.4%)	215 (76.0%)	73 (48.7%)	105 (70.0%)
Partially swallowed	38 (26.8%)	10 (7.1%)	24 (8.5%)	48 (32.0%)	38 (25.3%)
Spat out	5 (3.5%)	5 (3.6%)	15 (5.5%)	20 (13.3%)	0 (0%)
Swallowed the wrong	0 (00/)	0 (0%)	0 (00/)	2 (4 20/)	0 (00/)
way	ay 0 (0%)		0 (0%)	2 (1.3%)	0 (0%)
Refused to take	23 (16.2%)	13 (9.2%)	29 (10.3%)	7 (4.7%)	7 (4.7%)
Total	142 (100%)	141 (100%)	283 (100%)	150 (100%)	150 (100%)

Table 6: Deglutition results for different formulations, ODF: orodispersible film

	Study_1			Study_2	
Acceptability	Syrup	Mini-tablet	Oblong	Syrup	ODF
7 1000 p 1010			tablet		
	n (%)	n (%)	n (%)	n (%)	n (%)
High	39 (27.7%)	68 (48.6%)	121 (43.5%)	28 (18.7%)	22 (15.1%)
Good	27 (19.2%)	47 (33.6%)	98 (35.3%)	49 (32.7%)	59 (40.4%)
Low	12 (8.5%)	4 (2.9%)	12 (4.3%)	27 (18.0%)	47 (32.2%)
No	63 (44.7%)	21 (15.0%)	47 (16.9%)	46 (30.7%)	18 (12.3%)
Total	141 (100%)	140 (100%)	278 (100%)	150 (100%)	146 (100%)

Table 7: Acceptability results as composite endpoint for different formulations, ODF: orodispersible film

Results concerning good and high acceptability are graphically displayed in Figure 1.




Figure 1: Results of good or high acceptability as composite endpoint for different formulations, ODF: orodispersible film

Mini-tablet and oblong tablet show much better results compared to syrup and ODF when considering acceptability as 'good or high'. 'High' acceptability is clearly observed at higher rates for mini-tablet and oblong tablet compared to the other formulations.

The outcome of the newly developed acceptability definition as composite endpoint (regarding 'good or high' acceptability) is compared to the previously used definition of acceptability which was based on swallowability assessments only (refer to Figure 2).




Figure 2: Comparison of results of different definitions of acceptability:

Accept_previous: acceptability solely based on deglutition,

Accept_composite: acceptability as composite endpoint, ODF: orodispersible film

The newly defined composite endpoint method discriminates more between the four different formulation principles than the previous definition which was based on deglutition only: solid dosage forms, e.g., mini tablets and oblong tablets show higher acceptability over a liquid dosage form, e.g., syrup in children aged 2 days to 6 years.

Discussion

Starting in 2009 with a first prospective uncontrolled, single-dose study with a single 3 mm minitablets in 100 children aged 2 to 6 years, Thomson et al. [14] used an observation score distinguishing between "swallowed", "chewed", "spat out" or "refused to take". In further studies by other authors assessment methods included observations by parents, cares, patients with different assessment scores based on opinions or observation, visual analogue scales, or by trained investigators under highly standardized conditions and video observation [4]. Different parameters were assessed like acceptability, swallowability and palatability after formulation administration occurred with different vehicles like drinks or soft food.

Similar diverse attempts were made to investigate multiple mini-tablets and other oral galenic formulations like orodispersible films, tablets, oblong tablets, capsules, sprinkles, etc. The results of these studies are of different reliability and comparability [4].

Due to the lack of a validated approach, assessing and comparing acceptability of pediatric solid oral dosage forms is currently not possible [11]. This gap is intended to be closed with the proposed composite endpoint based on deglutition and palatability. Its suitability was demonstrated by evaluating data of two published studies [9,10] in children aged newborn to 6 years. The data of the underlying studies were based on validated, standardized assessment methods and followed the existing regulatory guidance's and requirements. The composite endpoint clearly increased the differentiation of acceptability for different pediatric oral formulations. Since previous studies

revealed sufficiently large inter-rater reliability, palatability as one component of the combined endpoint could also be assessed by only one rater of a video or other assessment methods like observation by a second investigator or facial hedonic scale in older children. To ensure the suitability of this composite endpoint for all age groups and for different oral formulations, a planned confirmatory, statistically powered study shall provide the evidence.

In summary, since the acceptability assessed as composite endpoint from standardized measurement procedures takes both - deglutition and palatability - into account, it is highly sensitive to detect differences between formulations. It is a well-defined and valid approach which appropriately and comprehensively meets regulatory requirements and is easy to apply in active pharmaceutical ingredients trial. The suitability of this composite endpoint should be broadly discussed to potentially enable alignment of competent authorities, sponsors and clinicians about the judgement on acceptability of pediatric solid oral formulations.

Especially with the application of the composite endpoint for acceptability in the reevaluation of the two studies it becomes obvious that the already started paradigm shift from oral liquid formulations to solid oral formulations in young children will lead to more patient-centric approaches in the development of better medicines for children.

Conclusions

With this composite endpoint a suitable, easy to apply, guideline-conform method to assess acceptability based on deglutition and palatability was established. This method is able to reliably detect differences between pediatric oral formulations, and may in future serve as a test system to enable patient centric drug development in pediatric populations.

Funding statement: None

Conflict of interest statement: No conflict of interest

Author contributions: Manfred Wargenau contributed substantially to the conceptualization, design and methodology of the article, to the data curation as well as formal analysis. He participated in the writing of the initial draft as well as in review and editing of the manuscript. Sibylle Reidemeister contributed substantially to the conceptualization, design and methodology of the article, as well as the funding acquisition. She participated in the writing of the initial draft as well as in review and editing of the manuscript. Ingrid Klingmann contributed substantially to the conceptualization, design and methodology of the article. She participated in the writing of the initial draft as well as in review and editing of the manuscript. Viviane Klingmann contributed substantially to the conceptualization, design and methodology of the article and had the oversight of the project. She participated in the writing of the initial draft as well as in review and editing of the manuscript.

References:

- Food and Drug Administration (US) Guidance for industry: general clinical pharmacology considerations for pediatric studies for drugs and biological products. Silver Spring (MD): FDA: 2014
- 2. European Medicines Agency, Guideline on pharmaceutical development of medicines for paediatric use. European Medicines Agency (EMA) CfMPfHU, 2013.
- 3. Ternik, Ret al., Assessment of swallowability and palatability of oral dosage forms in children: Report from an M-CERSI pediatric formulation workshop, International Journal of Pharmaceutics, 2018; 536: 570-581
- 4. Ranmal, SR et al., Methodologies for assessing the acceptability of oral formulations among children and older adults: a systematic review, Drug Discovery Today. 2018; 23:830-847.
- 5. Spomer N, et al., Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study, Archives of Disease in Childhood, 2012; 97:283-286
- 6. Klingmann V et al., Favourable acceptance of mini-tablets compared to syrup: a randomised controlled trial in small children, Journal of Pediatrics, 2013; 163:1728-1732
- 7. Klingmann V et al., Acceptability of uncoated mini-tablets in neonates a randomized controlled trial, Journal of Pediatrics, 2015;167:893-896
- 8. Klingmann V et al., Acceptability of multiple uncoated mini-tablets in infants and toddlers: A randomized controlled trial, Journal of Pediatrics, 2018; 201:202-207
- 9. Klingmann, V et al., Acceptability of an orodispersible film compared to syrup in neonates and infants: A randomized controlled trial. Eur J Pharm Biopharm, 2020; 151:239-245.
- 10. Münch, J et al., Acceptability of small-sized oblong tablets in comparison to syrup and mini-tablets in infants and toddlers: A randomized controlled trial. Eur J Pharm Biopharm, 2021; 166:126–134.
- 11. Timpe, C et al., Challenges and opportunities to include patient-centric product design in industrial medicine development to improve therapeutic goals, Br J Clin Pharmacol, 2020; 86:2020-2027.
- 12. Klingmann V, Acceptability of mini-tablets in young children: Results from three prospective cross-over studies. AAPS PharmSciTech, 2016; 18:263-266.
- 13. Kozarewicz P, Regulatory perspectives on acceptability testing of dosage forms in children. Int. J. Pharm, 2014; 469:245–248.
- 14. Thomson SA et al., Minitablets: new modality to deliver medicines to preschool-aged children, Pediatrics, 2009; 123(2):e235–e238.